Management prioritized investment in sales, marketing, and R&D to scale, while augmenting liquidity via warrant exercises and a shelf registration. This has funded growth but increased dilution risk. Stock-based compensation is notable relative to revenue, and outstanding warrants and options create an overhang.
We do not see evidence of value-destructive M&A, and capex remains minimal, but we want to see opportunistic repurchases or reduced SBC once free cash flow allows.







